Table 4.
Treatment | DSO | NDSO | MP | BP5 | BP10 |
---|---|---|---|---|---|
2nd day | 298.50 ± 2.93 | 298.83 ± 1.72 | 297.17 ± 2.47 | 296.67 ± 2.81 | 295.67 ± 3.52 |
4.94% | 4.83% | 5.36% | 5.52% | 5.84% | |
4th day | 280.50 ± 3.92 | 278.83 ± 2.44 | 273.33 ± 2.23 | 273.67 ± 2.23 | 271.17 ± 4.89 |
10.67% | 11.20% | 12.95% | 12.84% | 13.64% | |
6th day | 260.17 ± 3.04 | 253.67 ± 2.62 | 242.5 ± 3.12aA | 250.5 ± 2.42 | 238.8 ± 5.98aB |
17.14% | 19.21% | 22.77% | 20.22% | 23.94% | |
8th day | 239.17 ± 3.17 | 231.50 ± 3.18 | 208.0 ± 5.13aCbB | 226.3 ± 2.09 | 210.7 ± 4.97aCbB |
23.83% | 26.27% | 33.76% | 27.92% | 32.91% | |
10th day | 218.17 ± 2.87 | 207.00 ± 5.99 | 179.0 ± 5.63aCbB | 203.67 ± 2.19 | 175.3 ± 5.64aCbB |
30.52% | 34.08% | 42.99% | 35.14% | 44.16% | |
12th day | 193.17 ± 3.97 | 181.17 ± 5.13 | 140.2 ± 5.37aCbB | 173.50 ± 2.26 | 139.5 ± 6.76aCbC |
38.48% | 42.30% | 55.36% | 44.75% | 55.57% | |
14th day | 169.00 ± 4.76 | 152.33 ± 3.59 | 101.0 ± 5.64aCbC | 144.50 ± 2.28aA | 109.2 ± 5.15aCbC |
46.18% | 51.49% | 67.83% | 53.98% | 65.23% | |
16th day | 141.50 ± 5.25 | 126.50 ± 4.24 | 58.3 ± 6.02aCbC | 118.8 ± 1.85aA | 63.2 ± 5.64aCbC |
54.94% | 59.71% | 81.42% | 62.16% | 79.88% | |
18th day | 117.33 ± 4.25 | 102.50 ± 5.44 | 27.2 ± 2.34aCbC | 88.17 ± 3.19aC | 32.3 ± 2.92aCbC |
62.63% | 67.35% | 91.35% | 71.92% | 89.70% |
n = 6, Values are expressed as mean ± SEM, one way ANOVA, AP <0 0.05, BP < 0.01, CP < 0.001, aagainst DSO, bagainst NDSO, Abbreviations: DSO = Diabetic mice treated with Simple Ointment, NDSO = Nondiabetic mice treated with Simple Ointment, MP = Mupirocin ointment, BP5 = 5% BuddlejaPolystachya, BP10 = 10% BuddlejaPolystachya. Initial wound size was 314 mm2.